Market Intelligence, Clinical Progress, and High-Purity Reagents for Hemostasis and TAM Receptor Pathway Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PROS1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PROS1 Recombinant Protein. Full-length extracellular domain (GLA, EGF, SHBG-like). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Gamma-carboxylation). | View PROS1 Products |
| Mutant Library | PROS1 Deficiency Mutants (THPH5-associated variants: reduced secretion, undetectable expression, rs7614835). Pathological variants for mechanism studies. | View PROS1 Products |
| Gene Delivery | PROS1 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction and overexpression studies. | View PROS1 Products |
| Benchmark Ab | Anti-PROS1 (Neutralizing Reference). Recombinant monoclonal positive control for binding and blocking assays. | View PROS1 Products |
| Validator | PROS1 siRNA Set. For knockdown and specificity verification in cell-based assays. | View PROS1 Products |
| Related Target A | TYRO3. Primary TAM receptor tyrosine kinase for PROS1; essential for PROS1-mediated immune modulation assays. | View TYRO3 Products |
| Related Target B | AXL. TAM receptor for PROS1-driven tumor signaling and efferocytosis. | View AXL Products |
| Related Target C | MERTK. TAM receptor for PROS1-driven macrophage clearance and immunosuppression. | View MERTK Products |
| Related Target D | GAS6. Parallel TAM ligand; critical for comparative binding and selectivity counter-screening. | View GAS6 Products |
| Cofactor Complex | PROC (Protein C). Cofactor for PROS1 anticoagulant function validation. | View PROC Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native multi-domain folding for TAM receptor binding | HEK293-expressed PROS1 with >95% purity; Sequence Verified; Endotoxin <1EU/ug preserves EGF-like and SHBG-like domain integrity. |
| Gamma-carboxylation Integrity (Gla Domain Function) | HEK293 Expressed with Vitamin K Cycle Support. Mass Spec Verified for 11 Gla residues. |
| TAM Receptor vs Coagulation Selectivity | Purified PROS1 + TAM Receptor Panel (TYRO3/AXL/MERTK) available for competitive binding SPR. |
| Cross-species Preclinical Evaluation | Human/Mouse/Cyno PROS1 orthologs available with >95% purity and conserved domain sequences. |
| Lack of Neutralizing Controls | Anti-PROS1 recombinant reference antibody included for blocking assay standardization. |
| Deficiency Mechanism Modeling | Type I/II PROS1 Mutant Library (THPH5 variants) with Sequence Verification. |
| APC Cofactor Activity Measurement | Endotoxin-controlled (<1EU/ug) protein suitable for sensitive coagulation activity assays. |
Live PROS1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Thrombophilia Research
- TAM Signaling & Oncology Updates
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The therapeutic landscape for PROS1 (Protein S) is bifurcating between established hemostasis applications and emerging immuno-oncology opportunities. In hemostasis, congenital Protein S deficiency drives a persistent need for replacement biologics, with recombinant proteins offering improved gamma-carboxylation consistency over plasma-derived products. Concurrently, the elucidation of PROS1 as a bridging ligand for TAM receptors (TYRO3, AXL, MERTK) in tumor immune evasion is redirecting R&D toward antagonist modalities. As first-generation TAM tyrosine kinase inhibitors advance, the next wave targets ligand-level blockade—specifically the PROS1–TYRO3/MERTK axis—to overcome compensatory signaling and reduce on-target toxicities associated with pan-TAM catalytic inhibition. Future modalities include neutralizing monoclonal antibodies, decoy receptors, bispecifics, and gene therapy approaches.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Replacement | Grifols, Octapharma, Hemostasis biotechs | Congenital PROS1 Deficiency, Purpura Fulminans, Thrombophilia | Gla Domain Integrity Assay (Need HEK293-expressed, vitamin K-dependent PTM verification) |
| Monoclonal Antibody | Emerging immuno-oncology biotechs | Solid Tumors (TAM pathway blockade) | Receptor Blocking Assay (Need native glycosylated PROS1 with TAM-binding conformation) |
| Decoy Receptor (TAM-Fc) | Oncology pipeline developers | Metastatic Cancers | Heterodimer Competition (Need PROS1 + TYRO3/MERTK receptor panel) |
| Small Molecule (TAM TKIs) | BerGenBio, Mirati (via TAM targets) | Hematologic Malignancies, Solid Tumors | Ligand Selectivity Panel (Need PROS1 vs GAS6 discrimination assays) |
| Gene Therapy | Early academic, Rare disease focus | Severe Inherited Thrombophilia | Expression Validation (Need Lentivirus/ORF systems and siRNA controls) |
| Diagnostic Antibodies | Stago, HemosIL | Thrombophilia Screening, Free Protein S Quantification | Epitope Mapping (Need conformation-specific antigen) |